When 1517 Fund looks to invest in technology companies, one of our favorite questions is, “what’s to stop someone else from coming in and copying you?”
Pavle Jeremic had an incredibly exciting answer to that question. His firm, Aether Biomachines, is approaching control of 50% of all enzymatic data on Earth. In short order, they expect to reach 90%.
That means they’ll have a head start, and moat, on applying machine learning and neural networks to high potential information.
Pavle envisions this fundamentally changing the future of biological manufacturing for chemicals, food, and more.
He discusses all this with 1517 Fund’s Zak Slayback in this 50-minute conversation.
Connect with Pavle & Aether Biomachines
Connect with 1517 Fund